NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum, Tuesday, March 22, 2022 at 3:00pm Eastern Time. The format will be a "fireside chat" discussion hosted by KeyBanc’s Research Analyst Paul Knight.
Hamid Erfanian, Chief Executive Officer and David Bench, Chief Financial Officer, will be scheduling virtual 1x1 meetings on March 22. If you are interested in arranging a one-on-one meeting, please contact your KeyBanc representative.
A webcast of the presentation can be followed live via the following link:
Webcast Presentation Link –Click Here or please visit the “Upcoming Events” section within the “Investor Information” page of the Enzo Biochem website at www.enzo.com
About KeyBanc Capital Markets
KeyBanc Capital Markets has more than $50 billion of capital committed to clients and an award-winning Equity Research team that provides coverage on over 600 publicly-traded companies. Our clients benefit from our deep expertise across seven focused industry sectors, including Consumer & Retail, Healthcare, Industrial, Public Sector, Real Estate, and Technology. KeyBanc Capital Markets is a trade name under which corporate and investment banking products and services of KeyCorp and its subsidiaries, KeyBanc Capital Markets Inc., Member FINRA/SIPC, and KeyBank National Association (“KeyBank N.A.”), are marketed.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
For more information, please visit www.Enzo.com or follow Enzo Biochem on Twitter and
LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
###
Enzo Biochem Contacts
For: Enzo Biochem:
David Bench, CFO
212-583-0100
dbench@enzo.com
For Media:
Lynn Granito
Berry & Company Public Relations
212-253-8881
lgranito@berrypr.com
For Investors:
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
